

Abacavir + lamivudine + lopinavir + ritonavir

The Expert Committee, after evaluation, declines to list the medicine proposed in the application.

The Model List of Essential Medicines reports reasons that Committee Members have identified for denying listing.

Rejected

General description

INN

Abacavir + lamivudine + lopinavir + ritonavir

Medicine type

Chemical agent

EML status history

Application rejected in 2021 ([TRS 1035](#)) for [Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Wikipedia

[Abacavir + lamivudine + lopinavir + ritonavir](#)

DrugBank

[Abacavir](#),

[Lamivudine](#),

[Lopinavir](#),

[Ritonavir](#)

Recommendations

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 30 mg + 15 mg + 40 mg + 10 mg capsule containing oral granules

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)